Evaluation of the effects on peripheral and central haemodynamics parameters, safety, and tolerance of three-hour intravenous perfusion (0.1 mg/kg) of ivabradine given to severe congestive heart failure patients.
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2012
At a glance
- Drugs Ivabradine (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 15 Jun 2011 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
- 15 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Oct 2005 New trial record.